{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-085864","form_type":"8-K","ticker":"BCYC","cik":"0001761612","company_name":"BICYCLE THERAPEUTICS PLC","filed_at":"2022-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.950747+00:00","generated_at":"2026-06-24T04:22:26.987135+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Bicycle Therapeutics reports Q2 net loss $26.8M, cash $372.8M; Genentech expands collaboration","bullets":["Net loss $26.8M ($0.90/share) vs $17.9M ($0.74) in Q2 2021, driven by higher R&D and G&A costs.","Cash $372.8M as of June 30, 2022, down from $438.7M; expected runway into 2025.","Genentech exercised option to expand immuno-oncology collaboration, triggering $10M payment to Bicycle in Q3 2022.","BT8009 Phase I interim data: 50% ORR in urothelial cancer at 5.0mg/m2 weekly; four of five responders on therapy >24 weeks.","Expansion cohorts of BT5528 Phase I/II trial initiated; BT7480 Phase I/II poster presented at ASCO 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-085864","json":"https://secwatch.observer/filing/0001104659-22-085864.json","markdown":"https://secwatch.observer/filing/0001104659-22-085864.md","text":"https://secwatch.observer/filing/0001104659-22-085864.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761612/000110465922085864/0001104659-22-085864-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761612/000110465922085864/tm2222487d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T04:22:26.987135+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}